NASDAQ:LPCNLipocine Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lipocine Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.35 +0.06 (+4.65 %) (As of 07/16/2020 01:48 PM ET) Add Compare Share Today's Range$1.27Now: $1.35▼$1.4050-Day Range$0.88MA: $1.07▼$1.4552-Week Range$0.30Now: $1.35▼$3.45Volume36,834 shsAverage Volume2.31 million shsMarket Capitalization$64.64 millionP/E RatioN/ADividend YieldN/ABeta0.4 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase II testing; LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase I Clinical trial for the treatment of non-alcoholic steatohepatitis. Lipocine Inc. is headquartered in Salt Lake City, Utah.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingLipocine has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Lipocine has a potential upside of 122.2% from its current price of $1.35.Amount of Analyst CoverageLipocine has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesLipocine has received 276 “outperform” votes. (Add your “outperform” vote.)Underperform VotesLipocine has received 227 “underperform” votes. (Add your “underperform” vote.)Community SentimentLipocine has received 54.87% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote “Outperform” if you believe LPCN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LPCN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldLipocine does not currently pay a dividend.Dividend GrowthLipocine does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lipocine insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.50% of the stock of Lipocine is held by insiders.Percentage Held by InstitutionsOnly 7.61% of the stock of Lipocine is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lipocine are expected to grow in the coming year, from ($0.32) to $0.80 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lipocine is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lipocine is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLipocine has a P/B Ratio of 5.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.32 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LPCN Previous Symbol CUSIPN/A CIK1535955 Webwww.lipocine.com Phone801-994-7383Debt Debt-to-Equity Ratio0.72 Current Ratio5.16 Quick Ratio5.16Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$170,000.00 Price / Sales380.22 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book5.40Profitability EPS (Most Recent Fiscal Year)($0.50) Net Income$-13,010,000.00 Net MarginsN/A Return on Equity-206.04% Return on Assets-80.10%Miscellaneous Employees10 Outstanding Shares47,880,000Market Cap$64.64 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:LPCN Rates by TradingView Receive LPCN News and Ratings via Email Sign-up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Lipocine (NASDAQ:LPCN) Frequently Asked Questions How has Lipocine's stock been impacted by COVID-19 (Coronavirus)? Lipocine's stock was trading at $0.4511 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LPCN shares have increased by 199.3% and is now trading at $1.35. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Lipocine? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Lipocine. When is Lipocine's next earnings date? Lipocine is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Lipocine. How were Lipocine's earnings last quarter? Lipocine Inc (NASDAQ:LPCN) issued its quarterly earnings data on Thursday, May, 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.06. View Lipocine's earnings history. What price target have analysts set for LPCN? 2 brokers have issued 1 year price objectives for Lipocine's shares. Their forecasts range from $3.00 to $3.00. On average, they expect Lipocine's stock price to reach $3.00 in the next year. This suggests a possible upside of 122.2% from the stock's current price. View analysts' price targets for Lipocine. Has Lipocine been receiving favorable news coverage? Media coverage about LPCN stock has trended somewhat negative this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Lipocine earned a daily sentiment score of -1.9 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Lipocine. Who are some of Lipocine's key competitors? Some companies that are related to Lipocine include Pivot Pharmaceuticals (PVOTF), NextCure (NXTC), Northwest Biotherapeutics (NWBO), ProQR Therapeutics (PRQR), MediciNova (MNOV), Mallinckrodt (MNK), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Lannett (LCI), Verastem (VSTM), IVERIC bio (ISEE), REDHILL BIOPHAR/S (RDHL), Aduro BioTech (ADRO), TAIWAN LIPOSOME/S (TLC) and Lexicon Pharmaceuticals (LXRX). View all competitors. What other stocks do shareholders of Lipocine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Novavax (NVAX), SCYNEXIS (SCYX), Actinium Pharmaceuticals (ATNM), Catalyst Pharmaceuticals (CPRX), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX) and Cara Therapeutics (CARA). Who are Lipocine's key executives? Lipocine's management team includes the following people: Dr. Mahesh V. Patel, Co-Founder, Chairman, Pres & CEO (Age 62)Mr. Morgan R. Brown, Exec. VP, CFO & Corp. Sec. (Age 51)Logan Morse, VP of Sales, Marketing & Operations (Age 49)Nachiappan Chidambaram, VP of Product Devel. (Age 50)Dr. William I. Higuchi Ph.D., Chief Scientific Consultant (Age 88) What is Lipocine's stock symbol? Lipocine trades on the NASDAQ under the ticker symbol "LPCN." How do I buy shares of Lipocine? Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Lipocine's stock price today? One share of LPCN stock can currently be purchased for approximately $1.35. How big of a company is Lipocine? Lipocine has a market capitalization of $64.64 million and generates $170,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,010,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Lipocine employs 10 workers across the globe. What is Lipocine's official website? The official website for Lipocine is www.lipocine.com. How can I contact Lipocine? Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected] This page was last updated on 7/16/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
